As it was previously demonstrated, Avifavir® itself enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days of therapy but had little effect on the concentration of CRP, which is a marker of the severity of COVID-19 [3]. This evidence concerns the gene CRP and COVID-19.